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Abstract
Background: Parents struggle when making treatment decisions for children with arthritis or other chronic
conditions. Understanding their decision-making process is an essential step towards improving the decision-making
experience. The objective of this study was to describe parents’ information needs and the influences on their decision
making about treatment with TNF-α inhibitors.
Methods: Survey domains were developed based on qualitative data and cognitive interviewing. We mailed
the survey to parents of children with juvenile idiopathic arthritis or inflammatory bowel disease who had initiated
treatment with TNF-α inhibitors in the prior 2 years. Data were analyzed using descriptive and non-parametric statistics.
Results: Survey response rate was 54.9 %. Each item had <2 % missing responses. Parents used an array of information
sources when deciding about treatment with TNF-α inhibitors. Resources other than their child’s specialist were most
often used to increase confidence in parents’ decisions or because they wanted to know more about other
people’s experiences being treated with TNF-α inhibitors, rather than due to a lack of understanding. All but
two (cost and route of administration) of the influential decision factors were very or extremely important to
the majority of participants with factors related to long-term side effects, treatment efficacy, and disease impact being
most important.
Conclusions: This study describes parents’ information needs and influential factors in treatment decision making.
Results suggest that future work should be aimed at helping families weigh risks and benefits, such as through
decision support interventions, as well as developing opportunities to include people beyond the family and
physician in the decision-making process.
Background
Shared decision making is a key element of family-
centered care [1]. In order to participate in decision
making, parents need to be informed and prepared to
weigh the risks and benefits of treatment options. In the
setting of chronic conditions, parents often lack infor-
mation and may later reconsider difficult treatment deci-
sions [2–6]. Decisions about high-risk or lengthy
treatments may be particularly challenging and stressful
for parents [7, 8].
For families of children and adolescents with juven-
ile idiopathic arthritis (JIA) or inflammatory bowel
disease (IBD), our prior, qualitative research found
that the decision to start TNF-α inhibitors can be
particularly challenging [7, 9, 10] due to the need to
balance disease severity with side-effect risks [11–13].
As such, parents struggle to weigh the pros and cons.
This struggle continues after the decision is made, as
they continue to worry about the potential conse-
quences of their decision. In order to help them make
this challenging decision, parents report seeking infor-
mation from diverse sources, including the internet
and social contacts, [7] though the reasons they seek
this information are unknown. Our prior research fur-
ther suggested that the decision process, including
the information needs and decision-making influences,
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may differ between parents of children with JIA and
parents of children with IBD [7, 10].
These qualitative studies provided insight into parents’
decision-making experiences but were not intended to
be generalizable. Moving forward we wanted to ensure
that future interventions to address parents’ decision-
making needs and improve their experience are designed
with a full understanding of the influential factors in par-
ents’ decisions. Although others have assessed parents’ in-
formation needs related to specific diseases [14–17] and
general measures have been used to study the parent-
provider interaction, [18–20] there were no existing
measures or surveys that matched our desire to be able




Survey questions were developed based on our prior
qualitative interviews with families who had made deci-
sions about treatment with TNF-α inhibitors [7, 10] and
established models of shared decision making [21–23].
Specifically we sought to develop questions that captured
elements of the decision-making experience that occurred
both within and outside of the clinical encounter.
We generated a large pool of candidate questions
(n = 51) and then reviewed them systematically, com-
paring each to our aims and to other candidate questions,
to identify those that best fit the aims of our study without
being duplicative [24, 25]. The remaining pool of ques-
tions was reviewed by clinicians (n = 2), parents (n = 2)
and researchers with expertise in survey methods (n = 4).
During this process, questions underwent several iter-
ations to achieve face validity, the point at which all
members of the review team were satisfied that the
questions were complete and not duplicative in ad-
dressing our aims. These questions were divided into
two survey domains: Parents’ Information Needs and
Influential Decision Factors.
For each domain, the questions were tested via in-
person cognitive interviews with parents of children
with either JIA or IBD who had made a decision to start
treatment with TNF-α inhibitors. Parents were re-
cruited via referral from their child’s rheumatologist or
gastroenterologist with the goal of including parents
with diverse demographic characteristics, particularly in
relation to parent education and child’s age. Recruit-
ment continued until no substantial changes were
needed in three consecutive interviews. After obtaining
written consent, participants completed a “three-step
test-interview” [26] in which they first answered the
survey while describing out loud their thought process.
Next, the interviewer asked questions related to her ob-
servations (for example, why a participant paused while
answering a question). Finally, questions aimed at elicit-
ing their experiences and opinions were asked. In this
final step, participants were asked to complete tasks
such as rephrasing questions in their own words,
explaining the differences between similar questions
and telling about aspects of decision making that they
felt were not assessed in the survey. In analyzing the in-
terviews the study team looked for consistency between
verbal explanations and responses chosen, as well as ac-
curacy in rephrasing questions in the participant’s own
words. Parents were compensated $30 for participating
in cognitive interviewing. The survey was revised, as
described in the results, after every three interviews.
Final domains
Parents’ Information Needs focused on how and why in-
formation is obtained (Tables 2 and 3). We asked about
information resources using the following question:
“When deciding about treatment with TNF-α inhibitors,
how important was information from each of the follow-
ing people or resources…?” This was followed by a list of
information sources. Response options included “didn’t
use”, “not at all important”, “a little important”, “somewhat
important”, “very important” and “extremely important”.
We then asked “How often did you use sources of infor-
mation other than your child’s [gastroenterology/rheuma-
tology] provider…?” followed by a list of possible reasons.
Response options in this section were “never”, “rarely”,
“occasionally”, “pretty often” and “very often”.
Influential Decision Factors asked parents, “In making
the decision about treatment with biologics how important
was…?” followed by a list of potential decision factors
(Table 4). For most items the response options were “not
at all important”, “a little important”, “somewhat import-
ant”, “very important” and “extremely important”. For
questions related to specific potential side effects there was
an additional response option of “didn’t know about this.”
Parents received a survey that was specific to the disease
their child has, either JIA or IBD (see Additional file 1).
For example, questions referred to rheumatology for par-
ents of children with JIA and gastroenterology for parents
of children with IBD.
Sample
Parents of children with JIA or IBD who initiated treat-
ment with TNF-α inhibitors in the prior two years, at
either of two Midwestern children’s hospitals that serve
both local and national/international patients, were iden-
tified using disease registries and electronic medical re-
cords. One site chose to verify the pool of participants
by hand due to recent changes in the structure of their
disease registry. Parents of children who had a co-
morbidity that could also be treated with a biologic were
excluded, as were parents who had participated in
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cognitive interviewing. Patients with different names but
the same mailing address were assumed to be siblings.
In the case of siblings, we selected the sibling who had
most recently started TNF-α inhibitors and a survey was
sent addressed to that patient’s parents.
Survey procedures
Collaborating clinics mailed potential participants a letter
explaining the survey and how to opt-out of participation.
Parents who did not opt-out were then mailed a survey
along with a cover letter, a postage-paid return envelope
and a $2 bill. Completion of the survey constituted con-
sent to participate. Participants could decline to partici-
pate by calling the study coordinator or returning a blank
survey. A reminder postcard was sent a week later,
followed by a second copy of the survey. Non-responders
were then contacted via telephone and offered an oppor-
tunity to complete the survey over the phone [27]. Three
parents completed the survey over the phone.
This study was reviewed and approved by the Cincin-
nati Children’s Hospital Medical Center Institutional Re-
view Board which served as the institutional review
board of record for the study.
Data analysis
We used non-parametric statistics to assess for differ-
ences, in demographics or responses to individual ques-
tions, based upon disease. In assessing the percent of
responses missing for each question, we considered mul-
tiple responses or an unclear response, such as a mark
between 2 response options, to be missing for that ques-
tion. We addressed multiple comparisons by considering
only p-values <0.01 as significant. Descriptive statistics
were used for reporting response distributions. SAS 9.3
(SAS Institute Inc., Cary, NC) was used for all analyses.
Results
Survey development
Ten parents, five from each condition, participated in
cognitive interviews. Most changes were only minor
word or formatting alterations to improve readability.
We observed no significant difficulty in comprehension
of any question stem. For example, with the stem, “in
making the decision about treatment with biologics, how
important was…?” parents were able to correctly re-
phrase the question in their own words for both risks
and benefits.
A few questions were clarified through the interview-
ing process. For example, we found that parents distin-
guished between the ways treatment affects their child’s
daily life and the ways JIA or IBD affects their daily life.
Also, we asked parents both how important “the likeli-
hood that treatment with biologics would work for your
child” was and how important “the success rate of
treatment with biologics?” was, intending to use one ques-
tion to assess the importance of data to parents’ decisions.
However, parents consistently viewed these as two differ-
ent questions; the first related to the chance their specific
child would improve on TNF-α inhibitors and the second
related to the overall success in the population. For this
reason, both questions were retained in the final survey.
When the final survey was fielded, many questions had
no missing responses. Those that had missing responses,
for reasons other than the item not being applicable, were
each missing responses from <2 % of respondents.
Survey demographics
The final survey had a total of 201 respondents (response
rate 54.9 %). Children of responding parents had a mean
age of 13.9 years and had started TNF-α inhibitors a mean
of 17.4 months prior to the survey. 42.8 % of respondents
had a child with JIA. On average children with JIA were
younger than those with IBD, more likely to be female
and had started TNF-α inhibitors longer ago. Other
demographics were similar and all are listed in Table 1.
Overall there were few statistical differences when
comparing responses from parents whose children have
JIA to those whose children have IBD. Therefore results
from both diseases are grouped, with any between group
differences discussed in the text.
Parents’ information needs
The most commonly used information sources when
parents were deciding about treatment with TNF-α in-
hibitors were their child’s rheumatologist or gastroenter-
ologist (hereafter referred to as specialists), the nurse in
the specialist’s clinic, materials from the makers of TNF-
α inhibitors, and the internet, with the first three also
being the most important sources. Of the 62.7 % of par-
ents who used their child’s primary care provider as a
source of information, 19.8 % reported that the primary
care provider was an extremely important source of in-
formation and 23.0 % found them to be very important.
Of the 66.0 % of parents who used friends or family
members as a source of information, 9.1 % reported that
they were extremely important and 23.5 % very import-
ant. We found that significantly more parents of chil-
dren with JIA, compared to IBD, used the pharmacist as
an information source (p < 0.001). 99.0 % of respondents
found information from the specialist to be very or ex-
tremely important. More than 85 % also used the spe-
cialist’s nurse as an information source, with 64.6 %
finding information from the nurse to be very or ex-
tremely important. Information from the internet or ma-
terials from makers of TNF-α inhibitors was very or
extremely important to only 41.9 % and 54.2 % of re-
spondents who used those sources (Table 2).
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Table 1 Demographics




Total (n = 201) P Value*
Patient age, mean (SD), y 12.0 (4.9) 15.4 (3.1) 13.7 (4.0) <0.001
Months since starting treatment, mean (SD) 20.3 (8.1) 15.5 (7.4) 17.9 (7.8) <0.001
Patient sex, n (%) 0.003
Male 30 (34.9) 64 (56.1) 94 (47)
Female 56 (65.1) 50 (43.9) 106 (53)
Patient race, n (%) 0.32
White 77 (90.6) 98 (86.0) 175 (87.9)
Black/African American 5 (5.9) 7 (6.1) 12 (6.0)
Asian/American Indian/Pacific Islander 0 (0) 3 (2.6) 3 (1.5)
Mixed 3 (3.5) 3 (2.6) 6 (3.1)
Other 0 (0) 3 (2.6) 3 (1.5)
Patient ethnicity, n (%) 0.25
Hispanic 5 (5.8) 3 (2.6) 8 (4.0)
Non-Hispanic 81 (94.2) 112 (97.4) 193 (96.0)
Respondent relationship to patient 0.37
Mother 78 (91.8) 98 (85.2) 176 (88.0)
Father 6 (7.1) 15 (13.0) 21 (10.5)
Legal Guardian 1 (1.2) 2 (1.7) 3 (1.5)
Respondent education, n (%) 0.06
No college 13 (15.7) 9 (8.2) 22 (11.4)
Some college 22 (26.5) 23 (20.9) 45 (23.3)
College degree 25 (30.1) 47 (42.7) 72 (37.3)
Post-graduate degree 21 (25.3) 30 (27.3) 51 (26.4)
Other 2 (2.4) 1 (0.9) 3 (1.6)
*p-value comparing characteristics between IBD and JIA
Table 2 Parents’ information needs: use and importance of information sources
Among those using the resource
Didn’t Use
N (%)












0 (0) 0 (0) 1 (0.5) 1 (0.5) 28 (14.0) 170 (85.0)
Your child’s primary care provider 75 (37.3) 22 (17.5) 25 (19.8) 25 (19.8) 29 (23.0) 25 (19.8)
The [rheumatology/
gastroenterology] nurses
29 (14.4) 9 (5.2) 13 (7.6) 39 (22.7) 66 (38.4) 45 (26.2)
Your pharmacist 95 (47.3) 25 (23.6) 21 (19.8) 24 (22.6) 22 (20.8) 14 (13.2)
Friends and family members 68 (34.0) 22 (16.7) 26 (19.7) 41 (31.1) 31 (23.5) 12 (9.1)
Parents of children with [arthritis/
ulcerative colitis or Crohns disease]
86 (42.8) 9 (7.8) 27 (23.5) 25 (21.7) 39 (33.9) 15 (13.0)
Materials, such as brochures or
videos, from the makers of biologics
47 (23.5) 4 (2.6) 20 (13.1) 46 (30.1) 51 (33.3) 32 (20.9)
Advertisements 91 (45.5) 45 (41.3) 31 (28.4) 18 (16.5) 9 (8.3) 6 (5.5)
The internet 36 (17.9) 10 (6.1) 29 (17.6) 57 (34.6) 44 (26.7) 25 (15.2)
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We then asked respondents the specific reasons they
used sources of information other than their child’s spe-
cialist. The most frequent reasons for using other infor-
mation sources were to increase confidence in their
decision and because they wanted to know about other
people’s experiences being treated with TNF-α inhibitors.
Few parents used sources other than the specialist be-
cause they did not understand the information from the
specialist or did not remember what was said during the
visit (Table 3).
Influential decision factors
All potential decision factors, except out of pocket treat-
ment costs and the fact that TNF-α inhibitors are only
available as a shot or infusion, were very or extremely
important to more than half of respondents. The treat-
ment factors which the most parents (>95 %) considered
to be very or extremely important to the decision were
decreasing their child’s symptoms, the impact of disease
on their child’s day to day life, the likelihood that treat-
ment would work for their child and the overall success
rate of treatment with TNF-α inhibitors. Regarding the
importance of side effects to parents’ decisions, avoiding
long-term side effects from TNF-α inhibitors, the pos-
sible risk of cancer associated with treatment, and the ef-
fect of treatment on the child’s immune system were
very or extremely important to the most parents, al-
though 4.5, 6.0 and 0.5 % of parents respectively did not
know about each of those (Table 4). The only risk or
benefit with a statistically different response between dis-
eases was the location, such as home or hospital, of treat-
ment which was very or extremely important to more
parents of patients with JIA than with IBD (p <0.001).
Discussion
Parents’ information needs and their influential decision
factors are key components of the process they use to
make decisions about treatment with TNF-α inhibitors.
This survey, designed to assess information needs and
influential decision factors for this specific decision,
complements existing measures of the decision process
that tend to focus narrowly on the interaction between
patient and physician [28–30].
Medical decision making has often been conceptual-
ized as involving the patient and the healthcare provider
or, in the case of pediatrics, a triad of the patient, parent
and provider [23]. Our results suggest that such a model
is an oversimplification. Parents seek treatment informa-
tion from a diversity of people and sources. This finding
is consistent with studies in other medical situations,
such as parents of pediatric surgical patients and adults
undergoing cancer treatment, in which patients used a
variety of information sources [14, 31]. However, a
German study focused on families of children with
rheumatic diseases found that the general practitioner
was a source of information for approximately 90 %
of parents [16]. The difference in use of general prac-
titioner or primary care provider between that study
and ours may be due to differences in the health sys-
tems or related to the fact that our study investigated
a very specific decision, rather than general informa-
tion about the child’s condition.
There is an extensive body of literature around health
information-seeking behaviors but most studies are not
related to a specific decision. For example, some studies
have looked at the information seeking behaviors or in-
formation needs of parents whose children are seen in
the emergency department [17] or focused on medical
conditions, [5, 6, 32, 33] rather than a specific treatment
decision. We are unaware of other studies that quantify
the reasons parents, or other individuals, seek informa-
tion from sources other than their physician. Partici-
pants in our study often sought information to improve
their confidence and to understand others’ experiences,
rather than due to lack of understanding. This is consist-
ent both with our observational study showing that a
large part of the visit is spent on information delivery
[10] and with our interview data demonstrating parents’
worry and concern about the decision [7].
Although the disease processes and some of the treat-
ment options differ, [34–36] overall parents’ decision ex-
periences, including information sources used and
Table 3 Parents’ information needs: reasons for using information sources
Never N (%) Rarely N (%) Occasionally N (%) Pretty Often N (%) Very Often N (%)
To prepare for a [rheumatology/gastroenterology] visit 44 (22.0) 37 (18.5) 73 (36.5) 33 (16.5) 13 (6.5)
Because you did not understand the information from
the [rheumatology/gastroenterology] provider
86 (43.0) 69 (34.5) 38 (19.0) 6 (3.0) 1 (0.5)
Because you wanted more information than the
[rheumatology/gastroenterology] provider gave you
26 (12.9) 39 (19.4) 73 (36.3) 37 (18.4) 26 (12.9)
Because you did not remember what was said during
the visit about treatment with biologics
72 (36.0) 60 (30.0) 51 (25.5) 14 (7.0) 3 (1.5)
Because you wanted to know about other people’s
experiences being treated with biologics
26 (13.0) 24 (12.0) 70 (35.0) 50 (25.0) 30 (15.0)
To increase your confidence in your decision 18 (9.0) 19 (9.5) 67 (33.5) 50 (25.0) 46 (23.0)
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factors considered, were similar, regardless of whether
their child had JIA or IBD. This finding contrasts with
our prior qualitative work, likely due to the larger, more
diverse sample and reflects the importance of following
qualitative work with quantitative studies. The minimal
differences seen between diseases likely relate to differ-
ences in disease epidemiology [37, 38] and mode of de-
livery of the most frequently used biologic in each
disease (home injection for JIA versus infusion for IBD).
The overall similarities allowed us to combine disease
groups and provide the benefit of a larger, more
generalizable sample for the study. In general, when
recalling the influential decision factors, fewer parents
seemed to rate treatment logistics, such as cost, location
of treatment and route of administration, as very or ex-
tremely important compared to the importance given to
treatment risks and benefits. This indicates that, for
parents of children with either JIA or IBD, the weighing
of side effects and efficacy is a key aspect of their treat-
ment decision. The high degree of importance placed by
most parents, on most risks and benefits, may be part of
the reason parents report struggling with the decision,
even when some ultimately see there being no choice [7].
One intervention that may ameliorate some of this
struggle is the use of a decision aid, a structured tool de-
signed to provide unbiased information and help parents
determine their values related to treatment. Given that
few parents reported needing more information or not
understanding information from the healthcare provider,
a decision aid focused on decisions about TNF-α inhibi-
tors in JIA or IBD should focus less on information de-
livery and more on helping parents weigh the pros and
cons for their family. Specifically, exercises to clarify
their values, as related to the treatment decision, may




















The results of medical tests, such as blood work or x-rays 6 (3.0) 5 (2.5) 21 (10.5) 65 (32.3) 104 (51.7) -
How long your child would be treated with biologics 9 (4.6) 9 (4.6) 34 (17.2) 64 (32.3) 82 (41.4) -
The ability to change your child’s treatment or try other treatments
in the future
11 (5.5) 10 (5.0) 49 (24.6) 66 (33.2) 63 (31.7) -
The fact that biologics are only available as a shot or IV infusion 34 (16.9) 32 (15.9) 50 (24.9) 34 (16.9) 51 (25.4) -
The location, such as home or hospital, where your child could receive
treatment with biologics
23 (11.4) 30 (14.9) 47 (23.4) 49 (24.4) 52 (25.9) -
Your child’s age 21 (10.5) 22 (11.0) 35 (17.4) 58 (28.9) 65 (32.3) -
The out-of-pocket cost of treatment 39 (19.4) 26 (12.9) 48 (23.9) 40 (19.9) 48 (23.9) -
Risks and benefits
Decreasing the symptoms your child was having at the time 0 (0) 0 (0) 2 (1.0) 34 (16.9) 165 (82.1) -
Side effects your child had experienced with other kinds of medicationsb 16 (10.5) 13 (8.6) 23 (15.1) 38 (25.0) 62 (40.8) -
The ways [arthritis/IBD] affects your child’s day to day life 1 (0.5) 1 (0.5) 4 (2.0) 55 (27.8) 137 (69.2) -
The ways [arthritis/IBD] treatment affects your child’s day to day life 4 (2.0) 11 (5.5) 15 (7.5) 60 (30.2) 109 (54.8) -
[Preventing joint damage/preventing surgery] from [arthritis/IBD] 4 (2.0) 1 (0.5) 10 (5.0) 36 (18.0) 149 (74.5) -
How quickly biologics would be expected to work 5 (2.5) 6 (3.0) 28 (13.9) 63 (31.3) 99 (49.3) -
The likelihood that treatment with biologics would work for your child 1 (0.5) 1 (0.5) 3 (1.5) 46 (22.9) 150 (74.6) -
The overall success rate of treatment with biologics 1 (0.5) 1 (0.5) 7 (3.5) 59 (29.4) 133 (66.2) -
Your child’s risk of cancer from uncontrolled IBDc 2 (1.7) 5 (4.4) 6 (5.2) 33 (28.7) 69 (60.0) -
Avoiding short-term side effects of biologics 5 (2.5) 14 (7.0) 54 (27.1) 56 (28.1) 54 (27.1) 16 (8.0)
Avoiding long-term side effects of biologics 2 (1.0) 5 (2.5) 17 (8.5) 48 (24.1) 118 (59.3) 9 (4.5)
The risk of tuberculosis (TB) associated with treatment 6 (3.0) 19 (9.5) 34 (17.0) 44 (22.0) 78 (39.0) 19 (9.5)
The effect of treatment on your child’s immune system 1 (0.5) 7 (3.5) 16 (8.0) 62 (31.0) 113 (56.5) 1 (0.5)
The possible risk of cancer associated with treatment 0 (0) 7 (3.5) 15 (7.5) 30 (15.0) 136 (68.0) 12 (6.0)
Avoiding unknown side effects 5 (2.5) 10 (5.1) 43 (21.7) 50 (25.3) 90 (45.5) -
aIndicates this response was not an option
bMissing for 52 participants due to their child’s lack of experience with medication side effects
cQuestion only appeared on IBD version of the survey
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help parents determine treatment goals and weigh the
many risks and benefits they consider important to
the decision process [39]. The use of decision aids
has been associated with improved decision outcomes,
specifically increased knowledge and decreased deci-
sional conflict and uncertainty [40]. While our partici-
pants did not express a need for more knowledge, the
prior qualitative research indicates significant conflict
and uncertainty, [7, 41] perhaps due to the difficulty bal-
ancing influential decision factors. Future research could
also consider how a decision aid might help parents and
physicians include the pediatric patient in the decision
process. Currently there is only limited evidence regarding
the best method of engaging pediatric patients in decision
making [42].
The minimal differences seen between parents of
children with JIA and parents of children with IBD sug-
gest that the concepts included in our survey could be
adapted for other treatment decisions in pediatric
rheumatology or other chronic disease settings. Ques-
tions in the first domain, Parents’ Information Needs,
would require only minimal adaptations to be used for
other treatment decisions. However, Influential Deci-
sion Factors likely requires a more in-depth under-
standing of the decision context of interest prior to
adaptation.
We undertook a rigorous approach to survey develop-
ment including extensive testing prior to fielding. Des-
pite this, some individual questions, particularly in the
influential decision factors domain, could be considered
to demonstrate a floor or ceiling effect. While responses
that are skewed limit our ability to determine which
items are most important to parents, we feel this reflects
the challenges experienced by them and their inability to
prioritize decision factors.
Despite following recommended survey procedures [27]
that included multiple mailed and phone contacts, our
study is limited by its 54.9 % response rate. Furthermore,
this process may have introduced selection bias as the re-
search team knew who had responded to the survey. Un-
fortunately, due to the way one site verified their pool of
potential participants, we are unable to determine if non-
respondents varied systematically from respondents. Add-
itionally, using medical records and disease registries to
identify participants limited our sample to those who had
chosen to start TNF-α inhibitors, as the databases contain
no indicator of those who decline TNF-α inhibitors. As in
any retrospective study, there may be recall bias as parents
made this decision up to 2 years prior to receiving the sur-
vey. We attempted to minimize such bias by asking par-
ents how old their child was when starting TNF-α
inhibitors, to help trigger memories specific to that time.
Finally, while this work included only parents, children
and adolescents are an integral part of decision making in
the pediatric setting. Future work should seek to describe
their information needs and influential decision factors.
Conclusions
This survey, describing decision making about treatment
with TNF-α inhibitors, is the first to describe the decision-
making process for a specific pediatric chronic condition
treatment decision. As such, it offers new insight into the
challenges parents’ of children with JIA experience. The
information gained through this work provides a frame-
work for understanding parents’ decision-making process
and for developing future decision support interventions
that may incorporate opportunities to weigh risks and
benefits and to include decision participants other than
the parent, patient and physician. Furthermore, such inter-
ventions may have use beyond decisions about TNF-α in-
hibitors in JIA as the challenges related to this specific
decision are not dissimilar to those in other rheumatologic
decisions. In nearly every such decision there are trade-
offs to be made, opportunities for families to participate in
decision making and currently limited data on how best to
support family decision making. Through careful descrip-
tion of the current decision experiences, future interven-
tions will be able to better address parents’ decision-
making needs.
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